Open AccessRapamycin‐ameliorated diabetic symptoms involved in increasing adiponectin expression in diabetic mice on a high‐fat diet
Author(s) -
Gong FangHua,
Ye YanNa,
Li JinMeng,
Zhao HaiYang,
Li XiaoKun
Publication year - 2017
Publication title -
the kaohsiung journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.439
H-Index - 36
eISSN - 2410-8650
pISSN - 1607-551X
DOI - 10.1016/j.kjms.2017.05.008
Subject(s) - adiponectin , medicine , adipose tissue , fgf21 , endocrinology , insulin resistance , intraperitoneal injection , type 2 diabetes , diabetes mellitus , receptor , fibroblast growth factor
Recent studies showed that rapamycin improved diabetic complications. Here, we investigated the metabolic effects of rapamycin in type 2 diabetes model (T2DM) mice. Mice were treated with a daily intraperitoneal injection of rapamycin at 2 mg/kg or vehicle only for 3 weeks and were maintained on a high‐fat diet. The treated diabetic mice exhibited decreased body weight, blood glucose levels, and fat mass. FGF21 expression was suppressed in C57B/L6 mice, but adiponectin expression increased both in FGF21 KO and C57B/L6 mice. These results suggest that rapamycin may alleviate FGF21 resistance in mice on a high‐fat diet. The reduction of adipose tissue mass of the diabetic mice may be due to the increased adiponectin.